Navigation Links
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Date:2/20/2009

Response submitted within one month of FDA complete response letter

KENILWORTH, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has responded to the U.S. Food and Drug Administration (FDA) complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets, which was received in January 2009. SAPHRIS is under review for the acute treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.

The action letter included proposed labeling for both indications and a request for supplemental data from the existing asenapine database. No additional clinical trials were requested.

"We are pleased to have submitted the SAPHRIS complete response within a month from receipt of the FDA action letter. We look forward to working with the agency to finalize labeling and gain approval, and to bringing a new therapy to patients with schizophrenia and bipolar I disorder," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.

Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the antipsychotic agent. The New Drug Application (NDA) for asenapine includes data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania trials.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
2. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
3. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
4. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
5. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
6. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
7. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
8. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
9. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
10. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
11. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... how the receptors responsible for contractions in the bladder, ... published today in The FASEB Journal , has ... cycle of all cells in the body. The team ... and its control are weakened in ageing bladders, demonstrating ... ageing. , While currently much is known ...
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... , , NEW YORK, Sept. ... with Dave Champagne, Vice President and General Manager of Informatics ... Chief Engineer at HUNT Research Center and Biobank, about data ... and challenges at life sciences companies. , ...
... , , BALTIMORE, Sept. 9 ... a company engaged in the development of advanced preclinical platforms and ... present at Rodman & Renshaw,s Eleventh Annual Healthcare Conference taking place ... The company,s Chairman of the Board, Dr. David Sidransky, will present ...
... 9 Oramed Pharmaceticals,Inc. (OTCBB: ORMP.OB), a developer of ... approval from the Institutional Review Board (IRB),to commence human ... was,granted after successful pre-clinical results were reported. The trials ... Center in,Jerusalem. , Currently, all ...
Cached Biology Technology:Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 3Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 2Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 3
(Date:8/22/2014)... Access to Research Careers) Program has announced the travel ... Practical Exercises Workshop which will be held on the ... 2014. These awards are meant to help support ... groups in the the FASEB Grant Writing Seminar & ... awards totaling $20,350. , The FASEB MARC Program is ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... reconstructions of atmospheric CO2 concentrations and sea level over ... National Oceanography Centre, Southampton have found that greenhouse gas ... million) were systematically associated with sea levels at least ... determined the ,natural equilibrium, sea level for CO2 concentrations ...
... learn that plants grow toward the light. This seems straightforward, ... to grow and move in response to their environment are ... most fundamental processes in plant biologyplant movement in response to ... American Journal of Botany . Plant movements, known ...
... have cast doubt on the widely held perception that ... Blooms, or proliferations, of jellyfish can show a substantial, ... fishermen, stinging waters for tourists, even choked cooling intake ... have created a perception that the world,s oceans are ...
Cached Biology News:New study documents the natural relationship between CO2 concentrations and sea level 2Scientists join forces to bring plant movement to light 2Scientists join forces to bring plant movement to light 3Scientists join forces to bring plant movement to light 4Jellyfish experts show increased blooms are a consequence of periodic global fluctuations 2
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Request Info...
Biology Products: